![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
DR Beidler and YC Cheng
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Camptothecin (CPT) has been shown to induce protein-linked DNA breaks (PLDB), which are stabilized intermediates of topoisomerase I (TOP1) activity. Due to the reversible nature of PLDB and the need for replication fork movement for CPT toxicity, both the time of CPT exposure and TOP1 levels are determinants of CPT toxicity. Therefore, the effects of CPT exposure on TOP1 over time were examined in an established human cell line, KB. Using an in vivo KCl-SDS co- precipitation assay, it was determined that 1 hr of CPT exposure resulted in a concentration-dependent increase in PLDB that reached a maximum at 5 microM CPT. However, prolonged incubations with CPT revealed a concentration- and time-dependent decrease in CPT-induced PLDB formation. The most rapid loss of PLDB was within 6 hr. Neither aphidicolin nor cycloheximide cotreatments altered the PLDB decrease induced by CPT. Immunoblot analysis revealed a reduction in TOP1 protein upon CPT exposure, whereas RNA analysis revealed no changes, which suggested a post-transciptional mechanism of TOP1 down- regulation. The CPT-induced reduction was specific for TOP1, because actin and tubulin levels were unaltered by CPT exposure. Finally, clonogenic assays revealed a small but statistically significant decrease in CPT toxicity throughout the CPT exposure period. Because PLDB formation based on TOP1 levels is an important step in the toxicity of CPT, the CPT-induced TOP1 reduction could be a transient mechanism of resistance for cells to avoid toxic levels of PLDB.
This article has been cited by other articles:
|
|
 |
|
  S. D. Desai, L. M. Wood, Y.-C. Tsai, T.-S. Hsieh, J. R. Marks, G. L. Scott, B. C. Giovanella, and L. F. Liu ISG15 as a novel tumor biomarker for drug sensitivity Mol. Cancer Ther., June 1, 2008; 7(6): 1430 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-H. Miao, A. Player, U. Shankavaram, Y.-H. Wang, D. B. Zimonjic, P. L. Lorenzi, Z.-Y. Liao, H. Liu, T. Shimura, H.-L. Zhang, et al. Nonclassic Functions of Human Topoisomerase I: Genome-Wide and Pharmacologic Analyses Cancer Res., September 15, 2007; 67(18): 8752 - 8761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Kuo, J.-F. Liu, and J.-Y. Chang DNA Repair Enzyme, O6-Methylguanine DNA Methyltransferase, Modulates Cytotoxicity of Camptothecin-Derived Topoisomerase I Inhibitors J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 946 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Daud, N. Valkov, B. Centeno, J. Derderian, P. Sullivan, P. Munster, P. Urbas, R. C. DeConti, E. Berghorn, Z. Liu, et al. Phase II Trial of Karenitecin in Patients with Malignant Melanoma: Clinical and Translational Study Clin. Cancer Res., April 15, 2005; 11(8): 3009 - 3016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Kim, S.-Y. Park, C.-H. Hsu, G. E. Dutschman, and Y.-C. Cheng Synergistic Antitumor Activity of Troxacitabine and Camptothecin in Selected Human Cancer Cell Lines Mol. Pharmacol., August 1, 2004; 66(2): 285 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Christensen, R. M. Krokowski, H. U. Barthelmes, R. Hock, F. Boege, and C. Mielke Distinct Effects of Topoisomerase I and RNA Polymerase I Inhibitors Suggest a Dual Mechanism of Nucleolar/Nucleoplasmic Partitioning of Topoisomerase I J. Biol. Chem., May 21, 2004; 279(21): 21873 - 21882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-F. Zhang, A. Tomida, R. Koshimizu, Y. Ogiso, S. Lei, and T. Tsuruo Cullin 3 Promotes Proteasomal Degradation of the Topoisomerase I-DNA Covalent Complex Cancer Res., February 1, 2004; 64(3): 1114 - 1121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-K. Li, P. J. Houghton, S. D. Desai, P. Daroui, A. A. Liu, E. S. Hars, A. L. Ruchelman, E. J. LaVoie, and L. F. Liu Characterization of ARC-111 as a Novel Topoisomerase I-Targeting Anticancer Drug Cancer Res., December 1, 2003; 63(23): 8400 - 8407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rallabhandi, K. Hashimoto, Y.-Y. Mo, W. T. Beck, P. K. Moitra, and P. D'Arpa Sumoylation of Topoisomerase I Is Involved in Its Partitioning between Nucleoli and Nucleoplasm and Its Clearing from Nucleoli in Response to Camptothecin J. Biol. Chem., October 11, 2002; 277(42): 40020 - 40026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Debethune, G. Kohlhagen, A. Grandas, and Y. Pommier Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase Nucleic Acids Res., March 1, 2002; 30(5): 1198 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Hazlehurst, N. Valkov, L. Wisner, J. A. Storey, D. Boulware, D. M. Sullivan, and W. S. Dalton Reduction in drug-induced DNA double-strand breaks associated with {beta}1 integrin-mediated adhesion correlates with drug resistance in U937 cells Blood, September 15, 2001; 98(6): 1897 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Desai, T.-K. Li, A. Rodriguez-Bauman, E. H. Rubin, and L. F. Liu Ubiquitin/26S Proteasome-mediated Degradation of Topoisomerase I As a Resistance Mechanism to Camptothecin in Tumor Cells Cancer Res., August 1, 2001; 61(15): 5926 - 5932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang and F. Kiechle Hoechst 33342-Induced Apoptosis is Associated with Decreased Immunoreactive Topoisomerase I and Topoisomerase I-DNA Complex Formation Ann. Clin. Lab. Sci., April 1, 2001; 31(2): 187 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Larsen, C. Gilbert, G. Chyzak, S. Y. Plisov, I. Naguibneva, O. Lavergne, L. Lesueur-Ginot, and D. C. H. Bigg Unusual Potency of BN 80915, a Novel Fluorinated E-ring Modified Camptothecin, toward Human Colon Carcinoma Cells Cancer Res., April 1, 2001; 61(7): 2961 - 2967. [Abstract] [Full Text]
|
|
|
|
|
|
Q. Fu, S.-W. Kim, H.-X. Chen, S. Grill, and Y.-C. Cheng Degradation of Topoisomerase I Induced by Topoisomerase I Inhibitors Is Dependent on Inhibitor Structure but Independent of Cell Death Mol. Pharmacol., April 1, 1999; 55(4): 677 - 683. [Abstract] [Full Text]
|
|
|
|
|
|
K. Samejima, P. A. Svingen, G. S. Basi, T. Kottke, P. W. Mesner Jr., L. Stewart, F. Durrieu, G. G. Poirier, E. S. Alnemri, J. J. Champoux, et al. Caspase-mediated Cleavage of DNA Topoisomerase I at Unconventional Sites during Apoptosis J. Biol. Chem., February 12, 1999; 274(7): 4335 - 4340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Desai, L. F. Liu, D. Vazquez-Abad, and P. D'Arpa Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin J. Biol. Chem., September 26, 1997; 272(39): 24159 - 24164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Kaufmann, P. A. Svingen, S. D. Gore, D. K. Armstrong, Y.-C. Cheng, and E. K. Rowinsky Altered Formation of Topotecan-Stabilized Topoisomerase I-DNA Adducts in Human Leukemia Cells Blood, March 15, 1997; 89(6): 2098 - 2104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Edwards, A. Saleem, J. A. Shaman, T. Dennis, C. Gerigk, E. Oliveros, M. R. Gartenberg, and E. H. Rubin Role for Nucleolin/Nsr1 in the Cellular Localization of Topoisomerase I J. Biol. Chem., November 10, 2000; 275(46): 36181 - 36188. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
